ZA201201992B - Met inhibitors for enhancing radiotherapy efficacy - Google Patents

Met inhibitors for enhancing radiotherapy efficacy

Info

Publication number
ZA201201992B
ZA201201992B ZA2012/01992A ZA201201992A ZA201201992B ZA 201201992 B ZA201201992 B ZA 201201992B ZA 2012/01992 A ZA2012/01992 A ZA 2012/01992A ZA 201201992 A ZA201201992 A ZA 201201992A ZA 201201992 B ZA201201992 B ZA 201201992B
Authority
ZA
South Africa
Prior art keywords
met inhibitors
enhancing radiotherapy
radiotherapy efficacy
efficacy
enhancing
Prior art date
Application number
ZA2012/01992A
Other languages
English (en)
Inventor
Carla Boccaccio
Fiorella Petronzelli
Paolo Maria Comoglio
Santis Rita De
Original Assignee
Metheresis Translational Res S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res S A filed Critical Metheresis Translational Res S A
Publication of ZA201201992B publication Critical patent/ZA201201992B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA2012/01992A 2011-03-18 2012-03-16 Met inhibitors for enhancing radiotherapy efficacy ZA201201992B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy

Publications (1)

Publication Number Publication Date
ZA201201992B true ZA201201992B (en) 2015-05-27

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/01992A ZA201201992B (en) 2011-03-18 2012-03-16 Met inhibitors for enhancing radiotherapy efficacy

Country Status (22)

Country Link
US (1) US20120237524A1 (enExample)
EP (1) EP2500036B1 (enExample)
JP (1) JP5671487B2 (enExample)
KR (1) KR101540838B1 (enExample)
CN (1) CN102688491A (enExample)
AU (1) AU2012201303B2 (enExample)
BR (1) BR102012006063B1 (enExample)
CA (1) CA2769991C (enExample)
CY (1) CY1115374T1 (enExample)
DK (1) DK2500036T3 (enExample)
EA (1) EA028590B1 (enExample)
ES (1) ES2489475T3 (enExample)
HR (1) HRP20140729T1 (enExample)
IL (1) IL218293A (enExample)
MX (1) MX2012003084A (enExample)
PL (1) PL2500036T3 (enExample)
PT (1) PT2500036E (enExample)
RS (1) RS53468B (enExample)
SG (1) SG184637A1 (enExample)
SI (1) SI2500036T1 (enExample)
SM (1) SMT201400106B (enExample)
ZA (1) ZA201201992B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
CA2516236A1 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
US8609090B2 (en) * 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US8388958B2 (en) * 2006-02-06 2013-03-05 Metheresis Translational Research Sa Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Also Published As

Publication number Publication date
HRP20140729T1 (hr) 2014-08-29
EA201200329A3 (ru) 2013-01-30
JP2012196206A (ja) 2012-10-18
JP5671487B2 (ja) 2015-02-18
PT2500036E (pt) 2014-08-25
KR20120106582A (ko) 2012-09-26
CA2769991A1 (en) 2012-09-18
EP2500036B1 (en) 2014-05-07
PL2500036T3 (pl) 2014-10-31
CN102688491A (zh) 2012-09-26
SI2500036T1 (sl) 2014-09-30
KR101540838B1 (ko) 2015-08-06
ES2489475T3 (es) 2014-09-02
AU2012201303B2 (en) 2013-11-07
IL218293A0 (en) 2012-07-31
IL218293A (en) 2016-06-30
US20120237524A1 (en) 2012-09-20
DK2500036T3 (da) 2014-08-04
SMT201400106B (it) 2014-11-10
SG184637A1 (en) 2012-10-30
EA028590B1 (ru) 2017-12-29
EP2500036A1 (en) 2012-09-19
EA201200329A2 (ru) 2012-09-28
MX2012003084A (es) 2012-09-17
BR102012006063A2 (pt) 2021-11-16
HK1174539A1 (en) 2013-06-14
CA2769991C (en) 2018-05-15
RS53468B (sr) 2014-12-31
BR102012006063A8 (pt) 2022-11-08
AU2012201303A1 (en) 2012-10-04
BR102012006063B1 (pt) 2023-03-07
CY1115374T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
ZA201400232B (en) Metalloenzyme inhibitor compounds
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
TWI560172B (en) Neprilysin inhibitors
HUE060305T2 (hu) FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
PL2788343T3 (pl) Związki inhibitora metaloenzymu
EP2776126A4 (en) DEFINITION OF EFFECTIVE DEFIBRILLATION
IL233454A (en) Bromodomain Inhibitors
EP2804479A4 (en) METALLOENZYME INHIBITOR COMPOUNDS
ZA201201992B (en) Met inhibitors for enhancing radiotherapy efficacy
EP2894981A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
PL2804858T3 (pl) Związki - inhibitory metaloenzymu
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
ZA201306074B (en) Cathepsin c inhibitors
ZA201306415B (en) Peptide deformylase inhibitors
ZA201404044B (en) Peptide deformylase inhibitors
GB201120474D0 (en) Inhibitors
TWI561515B (en) Metalloenzyme inhibitor compounds
GB201104399D0 (en) Novel inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
IL225526A0 (en) Matrix metalloproteinase inhibitors
IL225528A0 (en) Matrix metalloproteinase inhibitors
IL225527A0 (en) Matrix metalloproteinase inhibitors